Business
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,478,873 additional shares, at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts a
About this update from Cytokinetics, Incorporated
[{"type":"image","alt":"Cytokinetics, Incorporated","displaySize":"","headline":null,"caption":"Cytokinetics, Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":131,"url":"https://media.zenfs.com/en/globenewswire.com/10a960ea96a50bea5c777e88dba3bc2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/J0pajxHwFe95Ug.L7DMD4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mw--/https://media.zenfs.com/en/globenewswire.com/10a960ea96a50bea5c777e88dba3bc2e","width":300,"height":131},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/J0pajxHwFe95Ug.L7DMD4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mw--/https://media.zenfs.com/en/globenewswire.com/10a960ea96a50bea5c777e88dba3bc2e","width":300,"height":131}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,478,873 additional shares, at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, were approximately $805 million. All of the shares of common stock in the offering were sold by Cytokinetics.","length":677,"tagName":"p"},{"type":"text","content":"Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies acted as joint book-running managers for the offering. Mizuho acted as lead co-manager for the offering and Citizens Capital Markets, Needham & Company, B. Riley Securities and H.C. Wainwright & Co. acted as co-managers for the offering.","length":316,"tagName":"p"},{"type":"text","content":"The securities described above were offered by Cytokinetics pursuant to a shelf registration statement (including a base prospectus) filed on February 27, 2025 with the Securities and Exchange Commission (SEC), which has become automatically effective. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and can be accessed for free on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospec...